{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:56:20Z","timestamp":1793976980517,"version":"4.8.0"},"reference-count":120,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation, pannus formation, and progressive joint destruction. Conventional therapies, including methotrexate, NSAIDs, and biologics, have improved outcomes but remain limited by incomplete efficacy, adverse effects, and resistance. Small interfering RNA (siRNA) has emerged as a promising strategy due to its ability to selectively silence pathogenic genes such as TNF-\u03b1, IL-1\u03b2, IL-6, IL-17, VEGFA, and key signaling pathways including NF-\u03baB, JAK\/STAT, and MAPK. Preclinical studies have shown that siRNA can suppress inflammation, reduce pannus formation, and protect cartilage; however, clinical translation is hindered by instability, nuclease degradation, poor biodistribution, and off-target effects. Nanocarrier-based systems offer solutions by improving siRNA stability, cellular uptake, and targeted delivery to inflamed joints. Lipid nanoparticles, PLGA, chitosan, and polyethyleneimine have been widely studied, while emerging carriers such as dendrimers, self-assembling peptides, mesoporous silica, and metal-organic frameworks (MOFs) further enhance controlled release and specificity. Functional modifications with ligands such as folic acid, hyaluronic acid, or RGD peptides enable active targeting, and stimuli-responsive designs allow pH-, ROS-, or enzyme-triggered release. Theranostic platforms also provide opportunities for real-time monitoring of biodistribution and therapeutic efficacy. Overall, siRNA-based nanomedicine represents a promising therapeutic paradigm for rheumatoid arthritis; however, its clinical translation remains constrained by several important challenges. Although current nanocarrier platforms demonstrate strong gene-silencing efficiency and encouraging anti-inflammatory outcomes in preclinical models, their behavior in humans is far less predictable. Key obstacles\u2014including systemic stability, protein corona formation, endosomal escape efficiency, batch-to-batch manufacturing consistency, and long-term biosafety\u2014must be rigorously addressed before clinical application can be realized. In addition, the heterogeneous nature of RA and its fluctuating inflammatory microenvironment imply that a single siRNA target or delivery strategy may not be universally effective across patient populations. Regulatory considerations also pose significant barriers, as siRNA nanomedicines must meet strict requirements for GMP production, quality control, sterility, pharmacokinetics, immunogenicity, and degradation profiling.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1718256","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:44:38Z","timestamp":1765953878000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Nanocarrier-based delivery of siRNA therapeutics in rheumatoid arthritis: immune mechanisms and translational perspectives"],"prefix":"10.3389","volume":"16","author":[{"given":"Longbin","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev277","article-title":"Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice","volume":"55","author":"Schaeverbeke","year":"2016","journal-title":"Rheumatol (Oxford)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3978","article-title":"Knocking down disease: a progress report on siRNA therapeutics","volume":"16","author":"Wittrup","year":"2015","journal-title":"Nat Rev Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B8","doi-asserted-by":"publisher","first-page":"214120","DOI":"10.1016\/j.bioadv.2024.214120","article-title":"siRNA-based nanotherapeutic approaches for targeted delivery in rheumatoid arthritis","volume":"168","author":"Sawan","year":"2025","journal-title":"Biomater Adv"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc Chem Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat Mater"},{"key":"B11","doi-asserted-by":"publisher","first-page":"149444","DOI":"10.1016\/j.cej.2024.149444","article-title":"3D printing of personalized magnesium composite bone tissue engineering scaffold for bone and angiogenesis regeneration","volume":"484","author":"Wang","year":"2024","journal-title":"Chem Eng J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2017.52","article-title":"A STING-activating nanovaccine for cancer immunotherapy","volume":"12","author":"Luo","year":"2017","journal-title":"Nat Nanotechnol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxq030","article-title":"IL-6: from its discovery to clinical applications","volume":"22","author":"Kishimoto","year":"2010","journal-title":"Int Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"108402","DOI":"10.1016\/j.intimp.2021.108402","article-title":"The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases","volume":"102","author":"Berry","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/BOR.0b013e328337c95a","article-title":"Angiogenesis and vasculogenesis in rheumatoid arthritis","volume":"22","author":"Szekanecz","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.mito.2023.10.004","article-title":"Role of mitochondrial dysfunction in the pathogenesis of rheumatoid arthritis: Looking closely at fibroblast- like synoviocytes","volume":"73","author":"Promila","year":"2023","journal-title":"Mitochondrion"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1039\/D0NR00454E","article-title":"A novel indomethacin\/methotrexate\/MMP-9 siRNA in situ hydrogel with dual effects of anti-inflammatory activity and reversal of cartilage disruption for the synergistic treatment of rheumatoid arthritis","volume":"12","author":"Yin","year":"2020","journal-title":"Nanoscale"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00816-x","article-title":"The immunology of rheumatoid arthritis","volume":"22","author":"Weyand","year":"2021","journal-title":"Nat Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12951-018-0382-x","article-title":"Combination of NF-kB targeted siRNA and methotrexate in a hybrid nanocarrier towards the effective treatment in rheumatoid arthritis","volume":"16","author":"Duan","year":"2018","journal-title":"J Nanobiotechnology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s42358-023-00325-z","article-title":"Baricitinib improves pulmonary fibrosis in mice with rheumatoid arthritis-associated interstitial lung disease by inhibiting the Jak2\/Stat3 signaling pathway","volume":"63","author":"Liu","year":"2023","journal-title":"Adv Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e19708","DOI":"10.7717\/peerj.19708","article-title":"MAPK\/ERK signaling pathway in rheumatoid arthritis: mechanisms and therapeutic potential","volume":"13","author":"Xie","year":"2025","journal-title":"PeerJ"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.01.029","article-title":"CaP-based anti-inflammatory HIF-1\u03b1 siRNA-encapsulating nanoparticle for rheumatoid arthritis therapy","volume":"343","author":"Liu","year":"2022","journal-title":"J Control Release"},{"key":"B25","first-page":"0035","article-title":"Intracellular Protein Delivery: Approaches, Challenges, and Clinical\nApplications","volume-title":"BME Front","author":"Chan","year":"2024"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.153","article-title":"Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment","volume":"8","author":"Schett","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.696802","article-title":"and modulating the PI3K\/AKT\/mTOR\/HIF-1\u03b1 Pathway","volume":"12","author":"Ba","year":"2021","journal-title":"Front Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02762","article-title":"DC32, a dihydroartemisinin derivative, ameliorates collagen-induced arthritis through an nrf2-p62-keap1 feedback loop","volume":"9","author":"Fan","year":"2018","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"155371","DOI":"10.1016\/j.phymed.2024.155371","article-title":"Dehydrocostus lactone alleviates irinotecan-induced intestinal mucositis by blocking TLR4\/MD2 complex formation","volume":"128","author":"Sun","year":"2024","journal-title":"Phytomedicine"},{"key":"B30","first-page":"699245","article-title":"INanomaterials Manipulate Macrophages for Rheumatoid Arthritis\nTreatment","volume-title":"Front Pharmacol","author":"Li","year":"2021"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2011.00052","article-title":"Macrophages in synovial inflammation","volume":"2","author":"Kennedy","year":"2011","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e2308520","DOI":"10.1002\/smll.202308520","article-title":"pH and ROS dual-sensitive nanocarriers for the targeted co-delivery and on-demand sequential release of tofacitinib and glucosamine for synergistic rheumatoid arthritis treatment","volume":"20","author":"Chen","year":"2024","journal-title":"Small"},{"key":"B33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1208\/s12248-021-00636-3","article-title":"Reactive oxygen species-responsive celastrol-loaded: bilirubin nanoparticles for the treatment of rheumatoid arthritis","volume":"24","author":"Zhao","year":"2021","journal-title":"AAPS J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010715-103633","article-title":"RNA interference (RNAi)-based therapeutics: delivering on the promise","volume":"56","author":"Bobbin","year":"2016","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1146\/annurev-phyto-080417-050044","article-title":"and applications in plant pathology","volume":"56","author":"Rosa","year":"2018","journal-title":"Annu Rev Phytopathol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrmicro.2015.14","article-title":"CRISPR-Cas adaptation: insights into the mechanism of action","volume":"14","author":"Amitai","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.08.034","article-title":"MicroRNA","volume":"141","author":"Lu","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/art.20975","article-title":"Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis","volume":"52","author":"Schiffelers","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2015.3985","article-title":"Targeted knockout of TNF-\u03b1 by injection of lentivirus-mediated siRNA into the subacromial bursa for the treatment of subacromial bursitis in rats","volume":"12","author":"Wang","year":"2015","journal-title":"Mol Med Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.biomaterials.2017.01.008","article-title":"Targeting NF-kB signaling with polymeric hybrid micelles that co-deliver siRNA and dexamethasone for arthritis therapy","volume":"122","author":"Wang","year":"2017","journal-title":"Biomaterials"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201801513R","article-title":"Critical role of IL-1\u03b1 in IL-1\u03b2-induced inflammatory responses: cooperation with NF-\u03baBp65 in transcriptional regulation","volume":"33","author":"Singh","year":"2019","journal-title":"FASEB J"},{"key":"B43","first-page":"0050","article-title":"NucleoCraft: The Art of Stimuli-Responsive Precision in DNA and RNA\nBioengineering","volume-title":"BME Front","author":"Yu","year":"2024"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-008-0131-3","article-title":"Comparison of anti-rheumatic effects of local RNAi-based therapy in collagen induced arthritis rats using various cytokine genes as molecular targets","volume":"19","author":"Inoue","year":"2009","journal-title":"Mod Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-013-0514-1","article-title":"IL-6 negatively regulates osteoblast differentiation through the SHP2\/MEK2 and SHP2\/Akt2 pathways in vitro","volume":"32","author":"Kaneshiro","year":"2014","journal-title":"J Bone Miner Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2018.9179","article-title":"Montelukast inhibits RANKL\u2212induced osteoclast formation and bone loss via CysLTR1 and P2Y12","volume":"18","author":"Kang","year":"2018","journal-title":"Mol Med Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B48","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.neuron.2019.03.020","article-title":"Therapeutic AAV gene transfer to the nervous system: A clinical reality","volume":"102","author":"Hudry","year":"2019","journal-title":"Neuron"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.addr.2016.06.011","article-title":"Recent progress in development of siRNA delivery vehicles for cancer therapy","volume":"104","author":"Kim","year":"2016","journal-title":"Adv Drug Delivery Rev"},{"key":"B51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J Nanobiotechnology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4103\/ATN.ATN-D-24-00030","article-title":"The role of long non-coding RNAs in angiogenesis in ischemic stroke: new perspectives based on advanced techniques in neuroscience","volume":"2","author":"Zhou","year":"2025","journal-title":"Advanced Technol Neurosci 2"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.8b00738","article-title":"Reduction-responsive polypeptide nanogel for intracellular drug delivery in relieving collagen-induced arthritis","volume":"4","author":"Feng","year":"2018","journal-title":"ACS Biomater Sci Eng"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo5284","article-title":"Tolerogenic nanoparticles induce type II collagen-specific regulatory T cells and ameliorate osteoarthritis","volume":"8","author":"Sohn","year":"2022","journal-title":"Sci Adv"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.5c06055","article-title":"Intelligently actuating dual-barrier hyaluronic acid-functionalized inflammation-responsive nanohydrogel for targeted rheumatoid arthritis therapy","volume":"17","author":"Singh","year":"2025","journal-title":"ACS Appl Mater Interfaces"},{"key":"B56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1620\/tjem.205.27","article-title":"Protective effects of prenatal administration of folic acid on retinoic acid-induced cellular damages of Meckel\u2019s cartilage in rats","volume":"205","author":"Firat","year":"2005","journal-title":"Tohoku J Exp Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/molecules28020591","article-title":"Macrophage-targeted dextran sulfate-dexamethasone conjugate micelles for effective treatment of rheumatoid arthritis","volume":"28","author":"Han","year":"2023","journal-title":"Molecules"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13578","article-title":"Vasoactive intestinal peptide-induced tolerogenic dendritic cells attenuated arthritis in experimental collagen-induced arthritic mice","volume":"22","author":"Wu","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.3.242","article-title":"Circulating soluble E-selectin in early rheumatoid arthritis: a prospective five year study","volume":"61","author":"Kuuliala","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1038\/s41467-021-22454-z","article-title":"Targeted apoptosis of macrophages and osteoclasts in arthritic joints is effective against advanced inflammatory arthritis","volume":"12","author":"Deng","year":"2021","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2017.07.087","article-title":"Chitosan as a bioactive polymer: Processing, properties and applications","volume":"105","author":"Muxika","year":"2017","journal-title":"Int J Biol Macromol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.220","article-title":"Chitosan\/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model","volume":"17","author":"Howard","year":"2009","journal-title":"Mol Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2011.12.014","article-title":"Drug targeting systems for inflammatory disease: one for all, all for one","volume":"161","author":"Crielaard","year":"2012","journal-title":"J Control Release"},{"key":"B64","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/mt.2013.245","article-title":"TNF-\u03b1 gene silencing using polymerized siRNA\/thiolated glycol chitosan nanoparticles for rheumatoid arthritis","volume":"22","author":"Lee","year":"2014","journal-title":"Mol Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.08.025","article-title":"Notch1 targeting siRNA delivery nanoparticles for rheumatoid arthritis therapy","volume":"216","author":"Kim","year":"2015","journal-title":"J Control Release"},{"key":"B66","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2147\/IJN.S146942","article-title":"In vivo therapeutic efficacy of TNF\u03b1 silencing by folate-PEG-chitosan-DEAE\/siRNA nanoparticles in arthritic mice","volume":"13","author":"Shi","year":"2018","journal-title":"Int J Nanomedicine"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2017.12.036","article-title":"Recent advances of PLGA micro\/nanoparticles for the delivery of biomacromolecular therapeutics","volume":"92","author":"Ding","year":"2018","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.2217\/nnm.11.90","article-title":"Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model","volume":"6","author":"Scheinman","year":"2011","journal-title":"Nanomedicine (Lond)"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.05.004","article-title":"MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model","volume":"161","author":"te Boekhorst","year":"2012","journal-title":"J Control Release"},{"key":"B70","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.nano.2019.102017","article-title":"Delivery of siRNA using folate receptor-targeted pH-sensitive polymeric nanoparticles for rheumatoid arthritis therapy","volume":"20","author":"Sun","year":"2019","journal-title":"Nanomedicine"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2012.038","article-title":"A simple and rapid nonviral approach to efficiently transfect primary tissue-derived cells using polyethylenimine","volume":"7","author":"Hsu","year":"2012","journal-title":"Nat Protoc"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e78619","DOI":"10.1371\/journal.pone.0078619","article-title":"Systemic delivery of small interfering RNA targeting the interleukin-2\/15 receptor \u03b2 chain prevents disease progression in experimental arthritis","volume":"8","author":"Zhang","year":"2013","journal-title":"PloS One"},{"key":"B73","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2217\/nnm.13.217","article-title":"Polyethyleneimine-functionalized iron oxide nanoparticles for systemic siRNA delivery in experimental arthritis","volume":"9","author":"Duan","year":"2014","journal-title":"Nanomedicine (Lond)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2012.08.008","article-title":"The use of anti-COX2 siRNA coated onto PLGA nanoparticles loading dexamethasone in the treatment of rheumatoid arthritis","volume":"33","author":"Park","year":"2012","journal-title":"Biomaterials"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.05.035","article-title":"Lipid nanoparticles with minimum burst release of TNF-\u03b1 siRNA show strong activity against rheumatoid arthritis unresponsive to methotrexate","volume":"283","author":"Aldayel","year":"2018","journal-title":"J Control Release"},{"key":"B76","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejpb.2019.06.009","article-title":"Lipidoid-polymer hybrid nanoparticles loaded with TNF siRNA suppress inflammation after intra-articular administration in a murine experimental arthritis model","volume":"142","author":"Jansen","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.05.002","article-title":"Lipidoid-siRNA nanoparticle-mediated IL-1\u03b2 Gene silencing for systemic arthritis therapy in a mouse model","volume":"27","author":"Song","year":"2019","journal-title":"Mol Ther"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1039\/C9BM01025D","article-title":"Nanoparticle-delivered siRNA targeting Bruton\u2019s tyrosine kinase for rheumatoid arthritis therapy","volume":"7","author":"Zhao","year":"2019","journal-title":"Biomater Sci"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-011-0589-0","article-title":"Comparison of polymeric siRNA nanocarriers in a murine LPS-activated macrophage cell line: gene silencing, toxicity and off-target gene expression","volume":"29","author":"Jensen","year":"2012","journal-title":"Pharm Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2016.10.033","article-title":"Systemic delivery of small interfering RNA targeting nuclear factor \u03baB in mice with collagen-induced arthritis using arginine-histidine-cysteine based oligopeptide-modified polymer nanomicelles","volume":"515","author":"Kanazawa","year":"2016","journal-title":"Int J Pharm"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2013.777779","article-title":"Silencing TNF-\u03b1 in macrophages and dendritic cells for arthritis treatment","volume":"42","author":"Ye","year":"2013","journal-title":"Scand J Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75673","article-title":"Peptide-siRNA nanocomplexes targeting NF-\u03baB subunit p65 suppress nascent experimental arthritis","volume":"124","author":"Zhou","year":"2014","journal-title":"J Clin Invest"},{"key":"B83","doi-asserted-by":"publisher","first-page":"102074","DOI":"10.1016\/j.mtbio.2025.102074","article-title":"Hyaluronic acid-anchored nanoparticles co-delivering emodin and siRNA confers protection against rheumatoid arthritis via macrophage polarization","volume":"33","author":"Qin","year":"2025","journal-title":"Mater Today Bio"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S382252","article-title":"A multifunctional nano-delivery system against rheumatoid arthritis by combined phototherapy, hypoxia-activated chemotherapy, and RNA interference","volume":"17","author":"Li","year":"2022","journal-title":"Int J Nanomedicine"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2012.207","article-title":"Biomolecular coronas provide the biological identity of nanosized materials","volume":"7","author":"Monopoli","year":"2012","journal-title":"Nat Nanotechnol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.actbio.2021.05.019","article-title":"The protein corona and its effects on nanoparticle-based drug delivery systems","volume":"129","author":"Li","year":"2021","journal-title":"Acta Biomater"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.11841","article-title":"siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review","volume":"46","author":"Sargazi","year":"2022","journal-title":"Cell Biol Int"},{"key":"B90","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1208\/s12248-019-0329-7","article-title":"Report of the AAPS guidance forum on the FDA draft guidance for industry: \u201cDrug products, including biological products, that contain nanomaterials","volume":"21","author":"de Vlieger","year":"2019","journal-title":"AAPS J"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-022-01262-y","article-title":"Nanomedicines and nanocarriers in clinical trials: surfing through regulatory requirements and physico-chemical critical quality attributes","volume":"13","author":"Dri","year":"2023","journal-title":"Drug Delivery Transl Res"},{"key":"B92","article-title":"Progress in nanomedicine: approved and investigational nanodrugs","volume":"42","author":"Ventola","year":"2017","journal-title":"P t"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1039\/c3cs60064e","article-title":"Cytokines as biomarkers of nanoparticle immunotoxicity","volume":"42","author":"Elsabahy","year":"2013","journal-title":"Chem Soc Rev"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1039\/D4NR04013A","article-title":"Multifunctional DNA nanomaterials: a new frontier in rheumatoid arthritis diagnosis and treatment","volume":"17","author":"Zhang","year":"2025","journal-title":"Nanoscale"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1039\/D4NR00680A","article-title":"Advances in engineered nanosystems: immunomodulatory interactions for therapeutic applications","volume":"16","author":"Khatua","year":"2024","journal-title":"Nanoscale"},{"key":"B96","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/ijms21020519","article-title":"Cancer nano-immunotherapy from the injection to the target: the role of protein corona","volume":"21","author":"Mikelez-Alonso","year":"2020","journal-title":"Int J Mol Sci 21"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00292","article-title":"Bioinspired shielding strategies for nanoparticle drug delivery applications","volume":"15","author":"Gulati","year":"2018","journal-title":"Mol Pharm"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.3c00940","article-title":"Engineered nanomaterials for immunomodulation: A review","volume":"7","author":"Singh","year":"2024","journal-title":"ACS Appl Bio Mater"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1039\/C9BM01643K","article-title":"Modulation of immune responses with nanoparticles and reduction of their immunotoxicity","volume":"8","author":"Muhammad","year":"2020","journal-title":"Biomater Sci"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.984252","article-title":"Lessons learned from immunological characterization of nanomaterials at the Nanotechnology Characterization Laboratory","volume":"13","author":"Dobrovolskaia","year":"2022","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.3c00329","article-title":"Protein corona formation on lipid nanoparticles negatively affects the NLRP3 inflammasome activation","volume":"34","author":"Debnath","year":"2023","journal-title":"Bioconjug Chem"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2024.2332730","article-title":"The potential application of complement inhibitors-loaded nanosystem for autoimmune diseases via regulation immune balance","volume":"32","author":"Wei","year":"2024","journal-title":"J Drug Target"},{"key":"B103","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.addr.2019.08.008","article-title":"Pharmacokinetics of nanotechnology-based formulations in pediatric populations","author":"Yellepeddi","year":"2019","journal-title":"Adv Drug Delivery Rev"},{"key":"B104","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0031-6997(24)01494-7","article-title":"Long-circulating and target-specific nanoparticles: theory to practice","volume":"53","author":"Moghimi","year":"2001","journal-title":"Pharmacol Rev"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.9b00368","article-title":"Lipid nanoparticle technology for clinical translation of siRNA therapeutics","volume":"52","author":"Kulkarni","year":"2019","journal-title":"Acc Chem Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N Engl J Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01943-z","article-title":"Vutrisiran: A review in polyneuropathy of hereditary transthyretin-mediated amyloidosis","volume":"83","author":"Nie","year":"2023","journal-title":"Drugs"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201115","article-title":"Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab","volume":"71","author":"Hogan","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0413-5","article-title":"Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes","volume":"16","author":"Nygaard","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.11.975","article-title":"Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10","volume":"61","author":"Tolboom","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"B114","doi-asserted-by":"publisher","first-page":"101906","DOI":"10.1016\/j.mito.2024.101906","article-title":"Cell-penetrating peptides with nanoparticles hybrid delivery vectors and their uptake pathways","volume":"78","author":"Dowaidar","year":"2024","journal-title":"Mitochondrion"},{"key":"B115","doi-asserted-by":"publisher","first-page":"102304","DOI":"10.1016\/j.coph.2022.102304","article-title":"Targeting fibroblast-like synoviocytes in rheumatoid arthritis","volume":"67","author":"Tsaltskan","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/art.24226","article-title":"Expression, regulation, and signaling of the pattern-recognition receptor nucleotide-binding oligomerization domain 2 in rheumatoid arthritis synovial fibroblasts","volume":"60","author":"Ospelt","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B117","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/j.celrep.2019.07.091","article-title":"Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes","volume":"28","author":"Lewis","year":"2019","journal-title":"Cell Rep"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/nature12873","article-title":"Genetics of rheumatoid arthritis contributes to biology and drug discovery","volume":"506","author":"Okada","year":"2014","journal-title":"Nature"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2014.10.024","article-title":"Molecular and cellular heterogeneity in the Rheumatoid Arthritis synovium: clinical correlates of synovitis","volume":"28","author":"Townsend","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.0c12341","article-title":"Protein nanoparticle charge and hydrophobicity govern protein corona and macrophage uptake","volume":"12","author":"Pustulka","year":"2020","journal-title":"ACS Appl Mater Interfaces"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1718256\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:44:41Z","timestamp":1765953881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1718256\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":120,"alternative-id":["10.3389\/fimmu.2025.1718256"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1718256","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"article-number":"1718256"}}